Aurobindo Pharma Limited has informed the Exchange regarding 'CuraTeQ Biologics receives approval for biosimilar Dyrupeg from UK s MHRA'.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has received marketing authorization from the UK's MHRA for Dyrupeg, a pegylated filgrastim biosimilar used in cancer care. This is CuraTeQ's third biosimilar approved by MHRA, following Bevqolva in December 2024 and Zefylti in May 2025. The product had earlier received EU approval in April 2025, making the UK approval a follow-on market access win. The approvals signal a maturing biosimilar pipeline from Aurobindo's biologics arm.
Positively builds Aurobindo's biologics franchise and opens a new revenue stream in the UK, a hard-currency market. No immediate financial guidance is given, so near-term impact is sentiment-driven and dependent on subsequent commercial uptake.